Intellipharmaceutics International Inc. et al

Intellipharmaceutics International Inc., in bankruptcy, reported a Statement of Affairs as at October 31, 2024 showing total assets of $1.00 against total liabilities of $7,486,435.76, with no secured or preferred claims and unsecured claims of $7,486,435.76, leaving a deficiency of $7,486,434.76. The unsecured claims pool is dominated by related-party and professional-fee debt, including $3,983,222.66 owed to directors Isa and Amina Odidi, $529,499.95 to Board Members, $741,392.15 to Buchanan Ingersoll & Rodney LLP, $559,811.92 to DLA Piper LLP (US), and $548,214.70 to Wollmuth Maher & Deutsch LLP, alongside numerous smaller trade, regulatory and exchange-related claims.